Literature DB >> 10067794

An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension.

K Narkiewicz1, V K Somers, L Mos, M Kato, V Accurso, P Palatini.   

Abstract

OBJECTIVE: To test the hypothesis that hemodynamic measurements in patients with essential hypertension are related independently to plasma leptin levels. PATIENTS AND METHODS: We measured plasma leptin, insulin, office and ambulatory blood pressure and heart rate in 60 men with untreated mild hypertension.
RESULTS: Plasma leptin correlated significantly with body mass index (r = 0.43, P = 0.001), 24 h heart rate (r = 0.35, P = 0.006) and 24 h diastolic blood pressure (r = 0.27, P = 0.04) but not with age (r = 0.03; P = 0.85) or 24 h systolic blood pressure (r = -0.08, P = 0.56). Plasma leptin levels adjusted for body mass index correlated significantly with 24 h heart rate (r = 0.36, P = 0.005) but not with 24 h diastolic blood pressure (r = 0.19, P = 0.15). We divided the patient population into tertiles of body mass index-adjusted plasma leptin levels. Age, plasma insulin, blood pressure, smoking status and physical activity habits were similar across the adjusted leptin tertiles. Patients from the third tertile of adjusted plasma leptin distribution (those with leptin levels higher than would be expected on the basis of body mass index) had significantly faster ambulatory heart rates than subjects from both the first and the second tertiles. The difference in heart rate across the three tertiles was most pronounced for the night-time values.
CONCLUSIONS: In patients with essential hypertension, heart rate is faster in those patients with higher plasma leptin levels. This relationship is independent of age, body mass index, insulin levels, blood pressure level, smoking status and physical activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067794     DOI: 10.1097/00004872-199917020-00009

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  8 in total

Review 1.  Obesity-related hypertension: role of the sympathetic nervous system, insulin, and leptin.

Authors:  Kazuko Masuo
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

2.  Baroreflex sensitivity and body growth parameters in children and adolescents.

Authors:  Z Nováková; N Honzíková; E Závodná; H Hrstková; P Václavková
Journal:  Exp Clin Cardiol       Date:  2001

3.  Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice.

Authors:  Eric J Belin de Chantemèle; James D Mintz; William E Rainey; David W Stepp
Journal:  Hypertension       Date:  2011-06-20       Impact factor: 10.190

Review 4.  Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease.

Authors:  P Palatini
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

Review 5.  Leptin: sympathetic and cardiovascular effects.

Authors:  Robert J Richards; Anthony Blalock; Jie Liao; Efrain Reisin
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

6.  Polymorphisms in the 3'UTR of the human leptin gene and their role in hypertension.

Authors:  Qulsum Akhter; Akbar Masood; Ruhi Ashraf; Sabia Majid; Sabah Rasool; Tanzeela Khan; Tabasum Rashid; A Syed Sameer; Bashir Ahmad Ganai
Journal:  Mol Med Rep       Date:  2012-01-04       Impact factor: 2.952

7.  Pressure mediated hypertrophy and mechanical stretch up-regulate expression of the long form of leptin receptor (ob-Rb) in rat cardiac myocytes.

Authors:  Hiroki Matsui; Tomoyuki Yokoyama; Chie Tanaka; Hiroaki Sunaga; Norimichi Koitabashi; Takako Takizawa; Masashi Arai; Masahiko Kurabayashi
Journal:  BMC Cell Biol       Date:  2012-12-27       Impact factor: 4.241

8.  Long Term High Fat Diet Treatment: An Appropriate Approach to Study the Sex-Specificity of the Autonomic and Cardiovascular Responses to Obesity in Mice.

Authors:  Thiago Bruder-Nascimento; Obioma J Ekeledo; Ruchi Anderson; Huy B Le; Eric J Belin de Chantemèle
Journal:  Front Physiol       Date:  2017-01-26       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.